CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 372 enrolled
Drug / intervention
Wearable activity sensor +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04094844
NCT04094844N/ACompleted
CompareCT.gov

A Randomized Trial of Roadmap 2.0

University of Michigan Rogel Cancer Center·interventional·Posted Sep 19, 2019·Updated Apr 14, 2026

In Brief

A clinical study evaluating Wearable activity sensor, Roadmap 2.0 information system, and 2 other interventions for Hematologic Diseases. Completed, enrolled 372 participants across 2 sites.

Detailed Summary

The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous hematopoietic cell transplantation (HCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Diseases
CountriesUnited States
CollaboratorsDepartment of Health and Human Services, National Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedSep 19, 2019
Enrollment StartSep 8, 2020
Primary CompletionAug 11, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.8 years ago

Interventions

Wearable activity sensorother

Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.

Roadmap 2.0 information systembehavioral

Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets

Survey administrationother

Caregivers and patients will be asked to respond to survey questions at 3 timepoints.

Roadmap 2.0 information system with Positive Activitiesbehavioral

Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.